Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
P29459
UPID:
IL12A_HUMAN
Alternative names:
Cytotoxic lymphocyte maturation factor 35 kDa subunit; IL-12 subunit p35; NK cell stimulatory factor chain 1
Alternative UPACC:
P29459; Q96QZ1
Background:
Interleukin-12 subunit alpha, also known as IL-12 subunit p35, plays a pivotal role in immune responses. It forms IL-12 by heterodimerizing with IL12B, crucial for T-cell and natural killer-cell activities, and IL-35 with EBI3/IL27B, vital for liver immune homeostasis. This protein is produced by antigen-presenting cells, including B-cells, dendritic cells, macrophages, and granulocytes, orchestrating the differentiation of T-helper 1 cells and linking innate resistance with adaptive immunity.
Therapeutic significance:
Understanding the role of Interleukin-12 subunit alpha could open doors to potential therapeutic strategies.